Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | STAT3 | P40763 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160350 | 0.82 | GAA (0.55) | KMT2AGAAMEN1SLC6A2SLC6A3 | |
| SCHEMBL5161662 | 0.75 | GAA (0.56) | KMT2AGAAMEN1SLC6A2SLC6A3 | |
| SCHEMBL30765190 | 0.74 | GAA (0.55) | KMT2AGAAMEN1SLC6A2SLC6A3 | |
| SCHEMBL27907982 | 0.73 | GAA (0.63) | KMT2AGAAMEN1SLC6A2SLC6A3 | |
| SCHEMBL29270879 | 0.73 | KMT2A (1.00) | KMT2AGAAMEN1SLC6A2SLC6A3 | |
| SCHEMBL6245092 | 0.73 | GAA (1.00) | KMT2AGAAMEN1SLC6A2SLC6A3 | |
| SCHEMBL22014136 | 0.73 | GAA (0.54) | KMT2AGAAMEN1SLC6A2SLC6A3 | |
| SCHEMBL4709927 | 0.72 | P2RX7 (0.48) | KMT2AHSD17B10 | |
| SCHEMBL4908980 | 0.72 | KMT2A (0.82) | KMT2AGAAMEN1SLC6A2SLC6A3 | |
| SCHEMBL18699858 | 0.72 | CYP1A2 (0.53) | KMT2AGAAMEN1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660504-B1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1660504-B1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | Agouron Pharmaceuticals,Inc. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | CCNA1, PGF, CCNA2 | KMT2A 2205/4885GAA 3177/4885MEN1 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.